Filtered By:
Source: Cancer Research
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 807 results found since Jan 2013.
Abstract 5370: The therapeutic strategy using Nek2 siRNA and 5FU for cholangiocarcinoma cell
Conclusion: The therapeutic strategy using Nek2 siRNA and 5FU may be an effective treatment option for cholangiocarcinoma. Further investigation is necessary to clarify the detailed mechanism regulating cell growth and death by a combination of Nek2 siRNA and 5FU.Note: This abstract was not presented at the meeting.Citation Format: Toshio Kokuryo, Yukihiro Yokoyama, Junpei Yamaguchi, Masato Nagino. The therapeutic strategy using Nek2 siRNA and 5FU for cholangiocarcinoma cell. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelph...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kokuryo, T., Yokoyama, Y., Yamaguchi, J., Nagino, M. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 707: Tumor-targeted delivery of siRNA using stabilized calcium phosphate nanoparticles based on bio-inspired hyaluronic acid conjugate
Conclusion Considering its biocompatibility, transfection efficacy, and tumor targeting capability, this stabilized organic-inorganic hybrid gene delivery platform should be considered a promising candidate carrier for systemic siRNA delivery and targeted cancer therapy.
Citation Format: Min Sang Lee, Jung Eun Lee, Eunkyoung Byun, Nak Won Kim, Haeshin Lee, Ji Hoon Jeong. Tumor-targeted delivery of siRNA using stabilized calcium phosphate nanoparticles based on bio-inspired hyaluronic acid conjugate. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Di...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Lee, M. S., Lee, J. E., Byun, E., Kim, N. W., Lee, H., Jeong, J. H. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 5519: Engineered protein nanocage for targeted delivery of siRNA to cancer cells
Considering the problems of small interfering RNA (siRNA) delivery using traditional viral and non-viral vehicles, a new siRNA delivery system to enhance efficiency and safety needs to be developed. Here we genetically engineered human ferritin based protein nanocage to simultaneously display various functional peptides on the surface of protein nanocage: cationic peptide to capture siRNA, tumor cell targeting and penetrating peptides, and enzymatically cleaved peptide to release siRNA inside tumor cell. In particular, we easily changed the tumor cell targeting peptide depending on target moiety [epidermal growth factor re...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Lee, E. J., Yang, Y., Kim, I.-s., Kim, K., Lee, J. Tags: Cancer Chemistry Source Type: research
Abstract B42: Silencing of DNA repair proteins with ECO/siRNA nanoparticles for the enhancement of radiation response in glioblastoma
In this study we investigate the use of these nanoparticles to deliver siRNA to inhibit ATM and DNApk activity and enhance radiation response in both glioma and glioma stem cell lines.Established glioma (U251) and glioma stem cell (NSC11) lines were used to evaluate the effectiveness of ECO nanoparticle delivery of siRNA in vitro . Cellular uptake of ECO nanoparticles loaded with fluorescent siRNA was assessed using flow cytometry and fluorescent microscopy, demonstrating the rapid uptake of ECO/siRNA nanoparticles in comparison to commercially available transfection agents. Protein and mRNA analyses revealed the kinetics ...
Source: Cancer Research - January 15, 2017 Category: Cancer & Oncology Authors: Jennifer A. Lee, Nadia Ayat, Anita Tandle, Zheng-Rong Lu, Kevin Camphausen Tags: Drug Delivery and Nanomedicine Source Type: research
Abstract P6-08-01: A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer
In conclusion, we identified INHBA as a major regulator of metabolism and aggressiveness in HER2+ basal breast cancer cells that is associated with poor outcome in patients.Citation Format: Korkola JE, Liu M, Smith R, Liby T, Heiser L, Gray JW. A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer [abstract]. In: Proceedings of the Thirty-Ninth Annual CTRC-AACR San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-08-01.
Source: Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: JE Korkola, M Liu, R Smith, T Liby, L Heiser, JW Gray Tags: Poster Session Abstracts Source Type: research
Abstract LB-103: L1CAM-targeted delivery of siRNA using elastin-like polypeptide (ELP) nanoparticles inhibits the growth of human tumors implanted in mice
Small interfering RNA (siRNA) drugs provide ideal means for perturbing intracellular oncogenic targets. However, specific delivery of siRNA to tumors has proven to be difficult. An ELP was engineered with an N-terminal region that binds to L1 cell adhesion molecule (L1CAM), and a C-terminal region that binds siRNA. Upon binding of siRNA, the L1CAM targeted ELP (ELP-L) spontaneously assembled into a spherical nanocomplex with the siRNA protected within, and the CAM-binding region protruding from the surface. These nanoparticles were used to deliver siRNA to SKOV3 tumors formed following surgical implantation of the cells in...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Primiano, T., Chang, B.-D., Heidel, J. D. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 4571: Antitumor effects of an antibody (cetuximab)-targeted nanoparticle containing siRNA against EGFR
Conclusions: NPs containing full antibodies as targeting agents and siRNA payloads can be formulated into well defined, stable experimental therapeutics. The NP system used here has a pH-tunable 5-nPBA that allows for targeting and stabilizing the NP at a physiologic pH of 7.4. The targeting agent and PEG coating is able to detach from the NP at acidic pH like those found in endosomes, enabling the siRNA payload to escape and reach its site of action within the cell. These NPs produce significant tumor regression in vivo that is superior to CTX alone.
Citation Format: Dorothy W. Pan, Mark E. Davis. Antitumor effects of an ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Pan, D. W., Davis, M. E. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract LB-13: Hyaluronic acid-based CD44 targeted nanoparticle delivery of combination MDR1 siRNA/paclitaxel to overcome drug resistance in ovarian cancer
A major obstacle in the success of chemotherapy in ovarian cancer is the emergence of multidrug resistance (MDR). Overexpression of the MDR1 gene and corresponding P-glycoprotein (Pgp) efflux pumps is one of the best characterized MDR mechanisms. Although MDR1 siRNA based strategies are emerging as highly promising approaches to reverse MDR, the systemic delivery still remains a great challenge. In the present study, CD44 targeting hyaluronic acid (HA) based self-assembling nanoparticle systems were designed with MDR1 siRNA to evaluate its delivery efficiency and combination anticancer therapeutic efficacy with paclitaxel ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Yang, X., lyer, A., hornicek, F., Amiji, M., Duan, Z. Tags: Cancer Chemistry Source Type: research
Abstract P2-07-04: Treatment of metastatic breast cancer using two nanoparticles combined with siRNA targeting Twist1 to inhibit EMT
Breast cancer is the 2nd leading cause of cancer related deaths among women in the US with over 240,000 diagnoses and 40,000 deaths expected in 2014. Among the more serious and deadly forms of breast cancer are the Triple Negative Breast Cancers (TNBC) (ER-, PR-, HER2-). Mortality rates among patients rise dramatically when these cancers spread beyond the primary tumor site. Therefore reduction of tumor cell dispersion is a key component to minimizing mortality rates. Epithelial-Mesenchymal Transition (EMT) is the process by which cancer cells downregulate proteins associated with cell to cell adhesion (e.g. E-cadherin) re...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Finlay, J. B., Roberts, C. M., Lowe, G., Peng, L., Zink, J. I., Tamanoi, F., Glackin, C. A. Tags: Poster Session Abstracts Source Type: research
Abstract LB-102: Layer-by-layer engineering of upconversion nanoparticle based siRNA and miRNA delivery system for cancer therapy
Conclusions: In this proof-of-concept study, a layer-by-layer engineered UCNP based siRNA and miRNA delivery system was successfully developed. Our novel delivery system opens up preparation of advanced UCNP based photoresponsive delivery systems that allow remote, precise, and trackable control over therapeutic payload (e.g., drug, gene) release for better cancer theranostics.Citation Format: Lin Min, YAN GAO, Francis J. Hornicek, Mansoor M. Amiji, Zhenfeng Duan. Layer-by-layer engineering of upconversion nanoparticle based siRNA and miRNA delivery system for cancer therapy. [abstract]. In: Proceedings of the 106th Annual...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Min, L., GAO, Y., Hornicek, F. J., Amiji, M. M., Duan, Z. Tags: Cancer Chemistry Source Type: research
Abstract 4410: An ICAM-1-targeted, Lcn2 siRNA-encapsulating liposome as a potent anti-angiogenic agent for triple-negative breast cancer
Conclusions: We have successfully engineered an immunoliposome that synergistically couples TNBC-targeting with Lcn2 siRNA silencing. Synthesized ICAM-Lcn2-LPs can significantly suppress in vitro and in vivo angiogenic activities of TNBC cells by regulating VEGF secretion. The modular design introduced here provides a basis for future TNBC-targeted therapeutics.Acknowledgements: This research is supported by NIH(NCI 1DP2CA174495) and the Breast Cancer Research Foundation.Citation Format: Peng Guo, Jiang Yang, Marsha Moses, Debra Auguste. An ICAM-1-targeted, Lcn2 siRNA-encapsulating liposome as a potent anti-angiogenic agen...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Guo, P., Yang, J., Moses, M., Auguste, D. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3653: Nanoparticle-delivered T7-synthesized siRNA enhances cell killing in HER-2 (+) breast cancer
In this study, a modified siRNA capable of both gene silencing and immunostimulation is the payload. Here, we test the hypothesis that ligand-directed, protein-based nanoparticles delivering siRNA launch a three-pronged attack on tumors by combining missile-like targeting (known as “transductional targeting”) with siRNA-mediated gene silencing, and cytokine-mediated cell death. The latter effect will be accomplished by taking advantage of the normally undesirable cytokine-mediated cytotoxicity induced by epigenetic modifications on certain forms of siRNA, and delivering this to tumors. Here we will deliver siRNA produc...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Alonso-Valenteen, F., , M.-K. Tags: Immunology Source Type: research
Abstract 5416: Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers
Successful siRNA based therapy has the potential to revolutionize cancer therapy by mediating the silencing of any gene deemed important for disease progression. However, unprotected siRNA has a short half-life in blood and lacks the ability to selectively identify target cells. Our group is developing an effective siRNA based nanoparticle platform that overcomes these shortcomings by utilizing a mesoporous silica nanoparticle electrostatically loaded with siRNA and conjugated with an antibody for target homing. The human epidermal growth receptor type 2 (HER2) is a highly validated therapeutic target in breast cancer due ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Goodyear, S. M. Tags: Cancer Chemistry Source Type: research
Abstract 1388A: Assessment of the anti-angiogenic effect of VEGFR2 siRNA in HUVEC using the Lonza 4D-Nucleofecto system
Angiogenesis is a hallmark of most cancers, and is thus an attractive target for the treatment of cancer. One of the easiest screening and target validation strategies for anti-angiogenic target identification involves knocking down targets in Human Umbilical Vein Endothelial Cells (HUVEC) and assessing subsequent effects on tube formation in Corning's Matrigel product.The usage of small interfering RNA (siRNA) is one of the strategies to knock-down RNA, and thereby protein expression within cells. siRNA can be delivered within cells using either chemical transfection or electroporation-based strategies such as the one off...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kokatam, S., Tiwari, K., Schroeder, J., Toell, A., Hussain, L., Kapoor, P. Tags: Tumor Biology Source Type: research
Abstract 3761: Nanoliposomal c-MYC-siRNA inhibits in vivo tumor growth of cisplatin-resistant ovarian cancer
Ovarian cancer is the deadliest of gynecological cancers in the United States. With fewer than 15% of cases diagnosed early, ovarian cancer continues to be characterized by late-stage presentation. Treatment for ovarian cancer usually involves surgical cytoreduction followed by platinum-based chemotherapy. Unfortunately, despite initial respond, more than 70% of ovarian cancer patients develop cisplatin resistance, relapse and therapeutic failure. Therefore, there is a need of novel therapies focused on targets within cancer cell survival pathways for advanced stage drug resistant ovarian cancer. Evidence indicates that ac...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Reyes–Gonzalez, J. M., Armaiz, G. N., Mangala, L. S., Valiyeva, F., Pradeep, S., Sood, A. K., Vivas–Meȷia, P. E. Tags: Experimental and Molecular Therapeutics Source Type: research
